You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

710 Results
Guidelines and Advice
Status: Current
ID: GL 1-25
Version: N/A
Mar 2023
Regimen
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
Sep 2023
Drug
Other Name(s): Onureg®
Aug 2023
Drug
Other Name(s): Polivy™
Dec 2022
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Oct 2023
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Jun 2022
Statistical Reports
Statistical Reports

Pages